Vericel Corp (VCEL): Total Liabilities
$133.33M
As of 2025-12-31
$132.82M
As of 2026-06-30
+18.2%
3-year compound annual growth
+13.3%
5-year compound annual growth
+27.0%
10-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $133.33M | -5.3% | 2026-02-26, Balance as of period end |
| 2024-12-31 | $140.75M | +10.2% | 2026-02-26, Balance as of period end |
| 2023-12-31 | $127.70M | +58.2% | 2025-02-27, Balance as of period end |
| 2022-12-31 | $80.73M | +10.2% | 2024-02-29, Balance as of period end |
| 2021-12-31 | $73.24M | +2.7% | 2023-02-23, Balance as of period end |
| 2020-12-31 | $71.35M | +69.3% | 2022-02-24, Balance as of period end |
| 2019-12-31 | $42.15M | +156.1% | 2021-02-24, Balance as of period end |
| 2018-12-31 | $16.46M | -48.6% | 2020-02-25, Balance as of period end |
| 2017-12-31 | $32.04M | +34.1% | 2019-02-26, Balance as of period end |
| 2016-12-31 | $23.89M | +96.2% | 2018-03-05, Balance as of period end |
| 2015-12-31 | $12.18M | +2.0% | 2017-03-13, Balance as of period end |
| 2014-12-31 | $11.94M | +124.4% | 2016-03-14, Balance as of period end |
| 2013-12-31 | $5.32M | -6.1% | 2014-03-13, Balance as of period end |
| 2012-12-31 | $5.67M | -72.6% | 2014-03-13, Balance as of period end |
| 2011-12-31 | $20.71M | n/a | 2013-03-18, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Vericel Corp (VCEL) | 2025-12-31 | $133.33M | -5.3% |
| Adaptive Biotechnologies Corp (ADPT) | 2025-12-31 | $287.74M | -14.6% |
| Iovance Biotherapeutics, Inc. (IOVA) | 2025-12-31 | $214.59M | +7.3% |
| Vaxart, Inc. (VXRT) | 2025-12-31 | $98.28M | -8.5% |
| Twist Bioscience Corp (TWST) | 2025-09-30 | $168.90M | +19.3% |
| Krystal Biotech, Inc. (KRYS) | 2025-12-31 | $114.23M | +4.4% |
| Immunocore Holdings plc (IMCR) | 2025-12-31 | $686.24M | +5.8% |
| Adaptimmune Therapeutics PLC (ADAPY) | 2024-12-31 | $234.11M | -3.7% |
| REGENXBIO Inc. (RGNX) | 2025-12-31 | $350.30M | +69.8% |
Compare VCEL, ADPT, IOVA, VXRT side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗